Page 1 of Clinical Trials for "Omalizumab", 98 Total Matches
- 1CompletedLast Updated: September 1, 2010Condition(s): Asthma
- 2CompletedLast Updated: September 14, 2011Condition(s): Chronic Urticaria
- 3CompletedLast Updated: November 3, 2011Condition(s): Asthma
- 4Active, not recruitingLast Updated: September 22, 2011Condition(s): Allergic Asthma
- 5TerminatedLast Updated: September 22, 2011Condition(s): Cystic Fibrosis; Allergic Bronchopulmonary Aspergillosis
- 6CompletedLast Updated: February 8, 2012Condition(s): Asthma
- 7CompletedLast Updated: June 3, 2008Condition(s): Asthma
- 8CompletedLast Updated: September 16, 2011Condition(s): Chronic Idiopathic Urticaria
- 9RecruitingLast Updated: April 18, 2012Condition(s): Cold Contact Urticaria
- 10RecruitingLast Updated: April 27, 2012Condition(s): Milk Allergy
- 11CompletedOmalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaLast Updated: June 28, 2011Condition(s): Asthma
- 12CompletedLast Updated: August 2, 2011Condition(s): Esophagitis
- 13CompletedLast Updated: June 24, 2011Condition(s): Asthma
- 14CompletedLast Updated: January 11, 2012Condition(s): Bullous Pemphigoid
- 15CompletedLast Updated: October 12, 2011Condition(s): Persistent Allergic Asthma
- 16Recruiting
- 17Not yet recruitingLast Updated: April 24, 2012Condition(s): Asthma
- 18CompletedLast Updated: March 13, 2012Condition(s): Eosinophilic Esophagitis
- 19CompletedLast Updated: February 11, 2011Condition(s): Interstitial Cystitis; Painful Bladder Syndrome
- 20CompletedLast Updated: May 5, 2011Condition(s): Allergic Asthma
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?intr=%22Omalizumab%22
